NCT06908304 - A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC | Biotech Hunter

Enrollment

300

Participants

Timeline

Start Date

November 3, 2025

Primary Completion Date

July 29, 2026

Study Completion Date

July 29, 2027

Conditions

Carcinoma, Non-Small -Cell Lung

Interventions

DRUG

6-Thio-2'-Deoxyguanosine

small molecule telomere targeting agent

DRUG

Cemiplimab

programmed cell death protein 1 (PD-1) inhibitor

DRUG

Docetaxel

Chemotherapy drug; inhibits cell division by stabilizing microtubules. Used for breast, lung, and prostate cancers.

DRUG

Vinorelbine

Chemotherapy drug; disrupts microtubule formation, inhibiting cell division. Used for non-small cell lung cancer and breast cancer.

DRUG

Gemcitabine alone

Chemotherapy drug; inhibits DNA synthesis. Used for pancreatic, lung, breast, and ovarian cancers.